Rein Therapeutics, Inc. Common Stock RNTX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Cost of Goods Sold by Product | ||||||
| License And Maintenance | $35K0.0% | $35K0.0% | $35K0.0% | $35K0.0% | $35K0.0% | |
| License | $25K0.0% | $25K— | —— | —— | —— | |
| Research And Development Expense by Product | ||||||
| Clinical Operation Activities | $5.57M+30.1% | $4.29M+1.7% | $4.21M-16.1% | $5.03M+41.4% | $3.56M-9.1% | |
| CMC Activities | $2.2M-1.8% | $2.24M+21.7% | $1.84M-26.9% | $2.52M-29.6% | $3.57M-19.4% | |
| Employee Related Expenses | $2M-5.8% | $2.12M-4.9% | $2.23M-1.7% | $2.27M+2.3% | $2.22M+0.7% | |
| Facilities And Other Expenses | $83K+12.2% | $74K0.0% | $74K+5.7% | $70K+14.8% | $61K+29.8% | |
| Professional Fees For Services | $27K-38.6% | $44K— | —— | —— | —— | |
| General And Administrative Expense by Product | ||||||
| Employee Related Expenses | $3.66M-2.3% | $3.75M+10.1% | $3.4M-5.7% | $3.61M-30.8% | $5.21M-4.6% | |
| Facilities And Other Expenses | $2M+1.9% | $1.96M-1.5% | $1.99M+4.0% | $1.92M-7.4% | $2.07M-3.4% | |
| Professional Fees For Services | $4.84M-6.7% | $5.19M-13.8% | $6.02M+35.9% | $4.43M-17.8% | $5.39M-13.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Rein Therapeutics, Inc. Common Stock break its business down?
- Rein Therapeutics, Inc. Common Stock (RNTX) reports cost of goods sold by product across 2 parts — License And Maintenance and License. Each is extracted from the segment footnotes and tracked over time.
- Where does Rein Therapeutics, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Rein Therapeutics, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.